



(51) International Patent Classification:

A61K 31/4178 (2006.01) *A61P 31/12* (2006.01)
A61K 31/4164 (2006.01) *A61P 31/00* (2006.01)

(21) International Application Number:

PCT/US2012/039835

(22) International Filing Date:

29 May 2012 (29.05.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/490,881 27 May 2011 (27.05.2011) US
61/504,905 6 July 2011 (06.07.2011) US
61/567,216 6 December 2011 (06.12.2011) US

(71) Applicant (for all designated States except US): **ACHIL-LION PHARMACEUTICALS, INC.** [US/US]; 300 George Street, New Haven, Connecticut 06511 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WILES, Jason Allan** [CA/US]; 33 James Street, Hamden, US 06518 (US). **WANG, Qiuping** [US/US]; 79 Carriage Drive, Bethany, Connecticut 06524 (US). **HASHIMOTO, Akihiro** [JP/US]; 47 Laurel Street, Branford, Connecticut 06405 (US). **PAIS, Godwin** [IN/US]; 2 Kaye Plaza, Apt. E1, Hamden, Connecticut 06514 (US). **CHEN, Dawei** [CN/US]; 158 Saddle Hill Drive, Middletown, Connecticut 06457 (US). **WANG, Xiangzhu** [CN/US]; 2 Runnymede Lane, Madison, Connecticut 06443 (US). **GADHACHANDA, Venkat** [IN/US]; 5121 Town Walk Dr., Hamden, Connecticut 06518 (US). **PHADKE, Avinash** [IN/US]; 51 Gilbert Lane, Branford, Connecticut

06405 (US). **DESHPANDE, Milind** [US/US]; 44 Field Brook Road, Madison, Connecticut 06443 (US).

(74) Agent: **MAXWELL, Leslie-Anne**; CANTOR COLBURN LLP, 20 Church Street 22nd floor, Hartford, Connecticut 06103 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

[Continued on next page]

(54) Title: SUBSTITUTED ALIPHANES, CYCLOPHANES, HETERAPHANES, HETEROPHANES, HETERO-HETERAPHANES AND METALLOCENES USEFUL FOR TREATING HCV INFECTIONS



(57) Abstract: The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula (I) D-M-D (Formula I) useful as antiviral agents. In certain embodiments disclosed herein M is a group -P-A-P- where A is (Formula I) Certain substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes disclosed herein are potent and/ or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions/ and combinations containing one or more substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes and a pharmaceutically acceptable carrier are also provided by this disclosure. Methods for treating viral infections, including Hepatitis C viral infections are provided by the disclosure.



Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*